BDTX — Black Diamond Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1701541 ·
Last close
$1.44
Market Cap
$82.75M
52W High
$4.06
52W Low
$1.39
ADV30
842,602
Next earnings
2026-11-10
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -12,122,000 -10,012,000 115,561,000 15,084,000 27,483,000
Jun 2026 0 — -12,057,000 -9,905,000 125,029,000 19,194,000 28,938,000
Mar 2026 0 — -11,259,000 -9,036,000 132,922,000 30,071,000 28,622,000
Dec 2025 0 — -10,262,000 -15,116,000 143,010,000 20,990,000 30,799,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-33,325,000
Investing CF
$17,705,000
Financing CF
$-152,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.77
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-493,693,000
Inventory
—
Receivables
—
ST Investments
$86,946,000
EBIT TTM
$-45,700,000
Pretax Income TTM
$-44,069,000
Interest Exp TTM
—
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-45,551,000
Free Cash Flow
$-23,302,500
Enterprise Value
$-1,515,665
Total Cash
$102,030,000
Total Debt
$16,036,000
Shares Out
57,468,255
Trailing EPS
$-0.77
Book Value
$1.53
ROE
-41.1%
ROA
-20.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 70,000,000 19,870,000 22,367,000 143,010,000 30,799,000 112,211,000 29,614,000
Dec 2024 0 -78,781,000 -69,676,000 122,640,000 39,355,000 83,285,000 -62,303,000
Dec 2023 0 -86,460,000 -82,442,000 158,567,000 41,831,000 116,736,000 -66,717,000
Dec 2022 0 -92,828,000 -91,169,000 156,255,000 40,560,000 115,695,000 -85,082,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-42,555,000
OpCashFlow TTM
—
Assets (Latest)
$125,029,000
Forward EPS
$-1.02

Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $1.50 · spot: $1.43 · call volume: 212 · put volume: 4
Expected Move to 2027-03-19: ±$1.27 (88.81%) — implied range $0.16 – $2.70 · ATM straddle on $1.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VXRT Vaxart, Inc. $86.51M $0.35 —
OTLK Outlook Therapeutics, Inc. $87.79M $0.36 —
CLLS Cellectis S.A. $77.08M $1.06 —
CHRS Coherus Oncology, Inc. $73.95M $0.48 —
TNYA Tenaya Therapeutics, Inc. $73.58M $0.32 —

News headlines (Yahoo Finance, 1h cache)

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
2026-11-12 21:01 · Yahoo
Black Diamond: Q3 Earnings Snapshot
2026-11-10 11:37 · Yahoo
Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update
2026-11-10 11:30 · Yahoo
Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC
2026-11-09 21:01 · Yahoo
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
2026-09-04 15:30 · Yahoo
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
2026-09-02 20:01 · Yahoo
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-05 20:01 · Yahoo
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
2026-05-21 23:09 · Yahoo
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
2026-05-27 15:13 · Yahoo
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
2026-05-19 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.